Innovation and Awareness Shaped the Diabetes Glucagon Market in Q3 2025

During Q3 2025, all five companies maintained corporate websites, while Fresenius Kabi, Novo Nordisk, and Xeris operated branded sites, with Novo Nordisk being the only one to manage an unbranded page. On social media, every company sustained a presence across all observed platforms.

Lupin expanded its U.S. injectable portfolio with the FDA-approved Glucagon launch while advancing the #HealWithLupin campaign to raise diabetes awareness through the RIIT program and educational polls.

Novo Nordisk reinforced its leadership in diabetes care through patient-driven campaigns like “Unordinary Drives Change” and partnerships, such as Cities for Better Health with the University of Oxford.

Xeris focused on hypoglycemia education and preparedness by promoting the Gvoke HypoPen, engaging patients through events and storytelling, and supporting the “Let’s Talk Lows” initiative with Beyond Type 1.